Aplagon

Preventing blood clots locally

Visit website
Investor data available

Who we are

Aplagon, based in Helsinki, Finland, is a pharmaceutical discovery and development company developing locally acting antithrombotic products (APACs) for the prevention of occlusions associated with blood vessel interventions. APACs are currently in late preclinical development. Aplagon is backed by leading Finnish life science investors Finnvera, Helsinki University Funds and Jenny and Antti Wihuri Foundation.

Our solution

Aplagon originates from the research on mast cell -derived heparin proteoglycans (HEP-PG) performed by Prof. Riitta Lassila’s group at Wihuri Research Institute in Helsinki, Finland. HEP-PGs reside in vascular tissue and take locally part in vascular repair and control of coagulation. APACs are tailor-made mimics of the natural HEP-PGs.

Benefits

Blood vessel occlusion following vascular interventions is a major clinical problem and a multibillion commercial opportunity. Our product, APAC, uniquely targets both acute and late complications of vascular interventions and acts locally at the site of the vascular injury. These unique features enable us to focus – within the vast blood vessel occlusion market – first on selected fast track indications, i.e. life threatening conditions without approved therapies.
 

What we are looking for

We are looking for partners for clinical studies.

Team profiles

Riitta Lassila, the inventor, is co-founder and CSO of Aplagon. Riitta is Head of Coagulation Disorders in Helsinki University Hospital and Professor in Coagulation Disorders in Helsinki University.

Aki Prihti, CEO, is one of the founders of Inveni Capital, a life sciences focused venture capital fund. Aki serves on the board of and has been involved in building several life science companies.

Contact information

Aki Prihti

CEO

aki.prihti(a)aplagon.com

+358 40 762 5159

www.aplagon.com/

Biomedicum Helsinki 2B, Tukholmankatu 8 B, 00290 Helsinki, Finland


Related posts